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ABSTRACT 
Objective: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are essential part of the administration of Rheumatoid Arthritis (RA). Methotrexate (MTX) 
is effective for tumor necrosis factor alpha (TNF-a) biologic agents, indicated only in minority of patients suffering from severe RA. MTX remains the 
"anchor drug" in the treatment of RA. For delivery improvement, novel pharmaceutical drug delivery system i.e. MTX-Cubosomes were developed.  
Methods: Poloxamer 407 and Glycerol monooleate (Monoelin, MO) used and the formulation were characterized as a sustained release drug 
delivery system for Methotrexate. Different ratios of Monolein, Poloxamer 407 and water were used to develop the different cubosomes using 
homogenization and emulsification method. Characterization of formulations for morphology was performed and also particle size distribution by 
Transmission Electron Microscopy (TEM). 
Results: Formulation showed the internal cubic structures of the vesicles. The particle size of the formulations was found to be ranging from 53.21 to 
185.32 nm, zeta potential of the formulations varied from-18.20-36.10 mV. The cubosomal formulation exhibited good entrapment efficiency along with 
high drug loading. Compatibility with the excipients was also established. An in vitro release study was done using Franz Diffusion cell indicated 
sustained release of the formulation at a rate of 1.25 %/h. Cubosomes proved to be reliable system for sustained transdermal drug delivery system.  
Conclusion: Methotrexate cubosomes is a novel medication delivery framework and in this examination it has been developed and characterized. 
The formulations were found to be promising in terms of its characterization parameters like particle size, zeta potential, entrapment efficiency, 
loading capacity, release kinetics, and stability, suitable for topical delivery.  
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INTRODUCTION  
RA is an autoimmune system sickness related with cutting edge 
incapacity, foundational inconveniences, early passing, and financial 
costs [1]. RA is an affliction depicted by methods for intense and constant 
fundamental disease that incorporates the joints, and affects tissues and 
organs that comprise of veins, heart, skin, lungs, and muscles. The 
beginning and seriousness of infection are alterable and tricky. RA at first 
bears with weakness, musculoskeletal agony, and firmness and after 
certain weeks to months it develops to include joints. The little joints are 
influenced first, the little bones of the fingers than the bigger joints are 
influenced, winds up swollen, warm, and painful [2]. Morning firmness 
or stiffness is additionally the signs and manifestations of RA and 
proposes enthusiastic illness. The influenced individual for the most part 
characterizes gradualness or challenge in development [3].  
It creates a fiery reaction of the synovium (synovitis) of synovial cells 
and the pannus improvement in the synovium. The pathology of the 
confusion once in a while prompts the decimation of articular ligament 
and ankylosis of the joints (wrists, shoulders, knees, lower legs and feet). 
RA can likewise affect different segments of the body in like manner 
joints and even delivers diffuse disease or irritation in the lungs, 
pericardium, pleura, and sclera, nodular sores, and in subcutaneous 
tissue. It is viewed as a systemic autoimmune system disease [4]. 
MTX is a robust anti-inflammatory and immunosuppressant drug 
that diminishes cell expansion, expanding adenosine discharge, and 
hinders catalysts of folate metabolism [21]. MTX adjusts the 
expression of cellular adhesion molecules, changes the generation of 
cytokines, and results on humoral reactions, and bone arrangement 
and affidavit [17] MTX is considered BCS class IV (Biopharmaceutics 
Classification System) medicate (hydrophobic medication with a low 
penetrability) [18] and is trying to manage because of the reality of 
instability and mild sensitivity [19]. The awful pharmacokinetics and 
assurance issues of the MTX limit its therapeutic impacts. The 
dangerous results on oral and gastrointestinal mucosa incorporate, 
stomatitis and seeping of the mucous films of the mouth or in 
gastrointestinal (GI) tract, ulcerations, enteritis and stomach trouble 
by method for conventional medication transport routes [29]. Oral 
absorption likewise is very low [3-6] and because of its concise 
complete half-life, [12] the transdermal use of MTX is by all accounts 
increasingly invaluable to accomplish good aid from pain.  
Cubosomes, cubic portion is an intriguing method for medication 
transport comprising of a bent relentless lipid bilayer reaching out 
in three dimensions and keeping separated two consistent systems 
of water channels [13–16]. It can encase hydrophilic, amphiphilic, 
and hydrophobic components going from little small-molecular-
weight drugs to proteins, peptides, amino acids, and nucleic acids 
[16]. Bi-phasic cubic stages are available in regular lipids, cationic 
[24] and nonionic surfactants, [25] and polymer framework, The 
primary pioneer of cubosome development is monoolein which is a 
blend of the oleic glycerides and other unsaturated fats comprises of 
the monooleate [26-28]. Cubic phase of cubosomes [29] as a result of 
its little pore size (5-10 nm) has an application for controlled 
release; and furthermore can solubilize hydrophobic, hydrophilic, 
and amphiphilic molecules; and has biodegradable activity [30]. It is 
emphatically bioadhesive [31] with great compatibility with topical 
and mucosal deposition and conveys dynamic fixings due to its skin 
penetration enhancing capability [32].  
Hence, the objective behind this study was to formulate topical 
cubosomes, novel delivery system that could help in Rheumatoid 
Arthritis improving absorption to the skin and simultaneously 
reduce the systemic diffusion of the skin-absorbed drug. 
MATERIALS AND METHODS 
Materials 
Methotrexate was a kind gift from IPC, India. Poloxamer 407, MO 
was obtained from Gattefose, France. Dialysis membrane (molecular 
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weight cut-off 12,000 g/mole) was purchased from Sigma Chemical 
Company (Sigma-Aldrich Corp., St. Louis, MO, USA). Polyvinyl 
alcohol, Potassium dihydrogen phosphate and disodium hydrogen 
phosphate was purchased from Sigma-Aldrich (Sigma-Aldrich Co., St. 
Louis, MO, USA). All other chemicals used were of analytical grade.  
Methods  
Preparation of methotrexate-loaded cubosomes nanoparticles 
Cubosomes Dispersions were made by emulsification of the cube-
like lipid part comprising of MO and Poloxamer 407 in water 
containing PVA 20 as appeared in table 1. The cubosomes were 
shaped by softening MO and Poloxamer 407 with the guide of hot 
plate kept up at 60 °C (MLH). At that point, the medication was 
dissolved down inside the melted blend. Distilled water containing 
2.5 %w/w PVA (low viscous cube-like part is accomplished by 
utilizing natural solvents, preheated at indistinguishable 
temperature) was added to the melted blend underneath mechanical 
mixing at 500 rpm. Dispersions were kept up under blending at 
temperature for 2 h to harden the lipid. The Dispersions were 
exposed to mixing at 15 000 cycles for each min at 60 °C for 1 min 
(Heidolph Homogenizers, Silent gadget M, and Germany). When the 
formulations were cooled, they were kept up at room temperature in 
glass vials. 
  
Table 1: Formulation table 
 S. No. Formulation code PLX: MO ratio PLX (%w/w) MO (%w/w) Plx and MO: water 
1)  F1 - 0.00 4.76 1:20 
2)  F2 1:6 0.68 4.08 1:20 
3)  F3 1:4 0.96 3.80 1:20 
4)  F4 1:2 1.58 3.18 1:20 
5)  F5 - 0.00 9.10 1:10 
6)  F6 1:6 1.30 7.80 1:10 
7)  F7 1:4 1.82 7.28 1:10 
8)  F8 1:2 3.04 6.06 1:10 
9)  F9 - 0.00 16.66 1:5 
10)  F10 1:6 2.38 14.28 1:5 
11)  F11 1:4 3.34 13.32 1:5 
12)  F12 1:2 5.56 11.10 1:5 
 
Characterization of methotrexate-loaded cubosomes  
Determination of pH  
Digital pH meter (Mettler Toledo, Langacher, Switzerland) was used 
for measuring the pH of the formulated Cubosomes. For this, each 
formulation was taken sufficiently to dip the electrode accurately 
and it was kept for 5 min to stabilize (n=6). 
Rheological behavior 
The rheological conduct of MTX-loaded cubosomes was discovered 
utilizing cone and plate rheometer (Brookfield DV3THB cone/plate 
rheometer) kept up at 25±2 °C and revolution were extended 
straightly from 0.5 to 200 rpm every moment. The MTX cubosomes 
conduct was investigated utilizing various models [21]. 
Drug excipients compatibility studies 
The drug compatibility with polymer was determined with the help 
of Fourier transform infrared (FTIR) spectra of Methotrexate and 
Methotrexate-loaded cubosomes were determined by using Perkin 
Elmer RX1 model. The pellets were prepared by gently mixing freeze 
dried formulation (1 mg) with 200 mg of potassium bromide and 
compacting at high pressure. The pellets thus prepared were 
scanned at a resolution of 4 cm-1 from 400 to 4000 cm-1 [33]. 
Shape and surface morphology 
The MTX cubosomes was observed under TEM to determine the 
surface morphology and size of the formulation. The formulation was 
diluted 50 times with double distilled water and stained negatively by 
phosphotungstic acid and then dried on the carbon coated grid. Excess 
of Phosphotungstic was removed using filter paper. Finally it was 
observed using Morgagni 268D (magnification x 2 50 000, Fei Electron 
Optics, Netherlands) transmission electron microscope [21]. 
Particle size, particle size distribution, polydispersity index 
(PDI) and zeta potential 
Cubosomes formulations were measured for the Particle size and its 
distribution, PDI and zeta potential of by Dynamic Light Scattering 
using Zetasizer (NanoZS90, Malvern Instruments Ltd. 
Worcestershire, UK). It was determined at a temperature of 25 °C 
and 90 ° fixed angle. Before the measurement, one drop of the 
sample (n=6) was taken from each selected formulation and diluted 
in 10 ml of the dispersion medium (distilled water) [21]. 
Entrapment efficiency and drug loading 
Cubosomes entrapment efficiency and drug loading were 
determined using high-speed centrifugation (Sigma 3K30, Osteorode 
am Harz, Germany) for 15 min at 15 000 rpm. Supernatant was 
separated once centrifugation is done and filtered using Millipore VR 
membrane (0.2 µm) [33]. Required dilution was done and it was 
analyzed (n=6) by HPLC [23] to examine MTX content at 303 nm. 
The entrapment efficiency (%) and drug loading was calculated by 
using the following equation 
Entrapment Efficiency (%w/w) = 
Amount of Encapsulated Drug
Total amount of the drug
 X100 
Drug Loading (%w/w) = 
Amount of Encapsulated Drug
Total amount of cubosomes
 X100 
In vitro drug release studies  
The MTX releases from cubosomes across dialysis cellulose membrane 
(molecular weight cutoff 12 000 g/mole) were performed by 
mounting it on vertical Hanson Franz diffusion cell system. The donor 
medium consisted of 1 g of vehicle containing Methotrexate. The 
diffusion area available between the cells was 1.785 cm2. The receptor 
compartment was filled with phosphate buffer (pH 7.4). The receptor 
medium was stirred at 200 rpm and the temperature was maintained 
at 37±0.5 °C. At fixed time intervals the receptor solution was sampled 
(n=6) and the receptor compartment replaced with fresh buffer 
simultaneously for the maintenance of sink condition. The withdrawn 
samples were analyzed using HPLC [34]. 
Release kinetics  
The drug release kinetics of Methotrexate Cubosomes was studied; the 
in vitro drug release study data was fitted to various kinetic models 
like, Higuchi matrix model, Hixon Crowell model, Korsmeyer-Peppas 
model and zero-order, first-order model. For each model, the 
correlation coefficient (R2) was calculated. The best fit model for the 
drug release was that giving R2 never to 1 was selected [35, 36].  
Stability studies 
The stability studies of the finalized formulations were done on the 
basis by ICH Q1A (R2) guidelines [45]. The samples of Methotrexate 
loaded cubosomes were stored under the following temperatures:  
a. 25±2 °C/65±5 %RH 
b. 40±2 °C/75±5 %RH; 
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in stability chambers (Thermolab, Mumbai, India) for 6 mo. 
Withdrawn samples at different time intervals i.e. 0, 1, 2, 3 and 6 mo 
were analyzed for particle size distribution, PDI, Entrapment 
efficiency, drug loading and phase separation [37]. 
RESULTS AND DISCUSSION 
Preparation of methotrexate cubosomes  
The MTX cubosomes were prepared according to the plan 
referenced in table 1. Surfactants, that were used in the plan of 
cubosomes, are poloxamer 407 of every an exceedingly focus differ 
somewhere in the range of 0 and 20 % w/w with respect to the 
scatter part. The grouping of the monoglyceride/surfactant blends 
normally takes between 2.5 % and 15 % w/w with respect to the 
whole weight of the scattering. Polyvinyl Alcohol (PVA) utilized 
despite poloxamer as a balancing out administrator of the 
dispersion. PVA structures little particles having uniform allocation. 
Also, it produces particles that are simply coursed in liquid medium. 
Stabilizers are routinely intertwined inside the cubosomal 
dispersion to change its surface properties and consequently 
invigorate. The modification of cubosomes nanoparticles by 
poloxamer 407 occurred utilizing surface adsorption of the 
polypropylene oxide copolymer's hydrophobic moieties into the 
outside surface of the cubosomes nanoparticles. 
Characterization of MTX cubosomes 
Determination of pH  
The pH of all the prepared cubosomes was measured (table 2) to 
ensure that it doesn’t affect the pH of the skin when applied 
topically. pH was measured to ensure that there is no irritation effect 
of the cubosomes on the skin. 
  
















1 F1 6.62±0.01 185.32±12.10 -18.20±1.27 64.39±0.94 11.22±1.34 2.93±0.21 0.754±0.03 
2 F2 6.41±0.05 93.90±3.90 -33.95±2.19  79.44±0.81 5.81±8.13 2.99±0.13 0.391±0.02 
3 F3 6.88±1.10 68.32±1.32 -31.75±0.92  80.31±0.72 6.41±9.28 3.14±0.17 0.427±0.03 
4 F4 6.71±1.40 23.21±0.89 -31.85±0.78  88.95±0.61 13.31±2.13 3.36±0.24 0.124±0.03 
5 F5 6.42±2.60 154.11±11.94 -32.70±0.14  60.39±0.24 12.01±0.36 3.41±0.13 0.652±0.05 
6 F6 6.32±1.90 168.75±3.72 -32.35±0.49  74.89±0.90 6.59±6.32 3.37±0.31 0.331±0.03 
7 F7 6.68±2.40 143.56±10.94 -31.00±0.71  77.62±0.53 6.46±0.29 4.13±0.18 0.215±0.06 
8 F8 6.94±1.30 130.71±8.35 -33.95±0.49  78.49±0.42 8.89±4.23 4.09±0.41 0.391±0.02 
9 F9 6.65±1.9 121.32±9.72 -28.20±0.14  60.99±0.94 10.92±2.19 6.63±0.48 0.731±0.03 
10 F10 6.39±2.4 78.21±5.47* -33.60±0.28  69.37±0.72 7.10±0.31 73.91±4.3 0.312±0.01 
11 F11 6.92±0.8 82.52±6.11 -36.10±2.97  70.63±0.44 7.52±7.32 79.97±4.9 0.286±0.03 
12 F12 6.77±1.4 83.32±6.28 -32.70±0.99  76.12±0.52 7.912.51 84.32±5.3 0.329±0.03 
 
 
Fig. 1: FTIR image showing A) Methotrexate standard B) Methotrexate loaded cubosomes 
 
Rheological behavior 
The rheological behavior of the formulations was assessed to study 
the spreadability of the formulation and its residence for longer 
time. Increased concentration of Monolein and Poloxamer 407 
showed better like consistency that increases the formulation 
viscosity (table 2). All the formulations have viscosities in the range 
that will provide better penetration.  
Drug excipients compatibility studies 
FTIR Spectroscopy of Methotrexate and Methotrexate loaded 
Cubosomes is presented in fig. 1. Strong and characteristic 
absorbance can be seen with Standard Methotrexate showing IR 
peaks at 1644 cm-1 and 1603 cm-1. Absorption peaks between 2500 
cm-1 and 3000 cm-1indicative of unchanged excipients property. 
Spectra of cubosomes altered with Methotrexate show expanded 
absorbance at 1600 cm-1 and the presence of another top at 1490 
cm-1 demonstrates the nearness of Methotrexate on the cubosomes. 
The intensity and the number of the peaks were found to be reduced 
suggesting possible interactions of the excipients with Methotrexate 
thereby reducing the crystalline nature and making the drug 
amorphous helpful in better absorption. 
Shape and surface morphology 
The surface morphology and mean distance across of the Methotrexate 
stacked cubosomes was imaged utilizing TEM. TEM pictures 
demonstrated nearly cube shape like surface of the detailing with 
uniform distribution for example<200 nm (table 2) and it supported the 
molecule size estimation by the zetasizer. The outcomes demonstrate 
the particles were consistently appropriated and isolated from one 
another. Decreased molecule size of the definition F4 was because of the 
nearness of higher grouping of Poloxamer 407 which was adsorbed on 
surface going about as a covering layer that balances out the little 
cubosomes nanoparticles surface [21]. Decreased Poloxamer 
concentration brought about the expansion of molecule size which was 
because of the increment in interfacial pressure consequently bringing 
about aggregation expanding the molecule size. All the cubosomes at the 
magnification as high as 2 50 000x were found not circular or round, 
they showed a cube like structure. TEM photomicrograph of the MTX 
loaded cubosomes is given in fig. 2. 
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Fig. 2: Transmission electron microscopy images 
 
Particle size and polydispersity index  
The particle size of the formulations was found to be ranging 
between 53.21±0.8 nm to 185.32±12.1 nm (fig. 3) and PDI was 
found ranging from 0.214±0.03 to 0.754±0.03 (table 2). 
Reduction in the surface tension between the lipid phase and the 
aqueous phase due to increase in the surfactant concentration 
might have lead to reduction of particle size. High surfactant 
concentration has also caused reduction in the steric 
hinderances [36, 37]. 
 
  
Fig. 3: Size distribution and zeta potential of cubosome 
 
Zeta Potential of the formulations were found ranging from-
18.20±1.27 to-33.95±2.19 (n=6) (table 2). Zeta potential indicates 
the stability of the dispersed particles in dispersion medium. High 
zeta potential shows high repulsion between the particles and 
particle aggregation is less likely to occur. A negative value of the 
zeta potential shows that formulations have good stability and 
dispersion quality.  
Entrapment efficiency and drug loading 
Different formulations were differentiated by determining the 
amount of drug incorporated in the formulation. The encapsulation 
efficiency of the formulations was found between 60.39±0.24 and 
88.95±0.61 % (table 2). As the drug is lipophilic in nature it is found 
that the encapsulation efficiency was high. The drug loading capacity 
was found to be varying from 5.81±8.13 to 12.01±0.36 %. Binary 
lipid matrices showed high loading and entrapment efficiency of the 
cubosomes [24]. 
In vitro drug release  
In vitro drug release study profile of the cubosomes in the initial 
stage showed (fig. 4) controlled release upon contact with bulk 
release media. No burst drug release indicated the entrapment of the 
drug in the lipid layer and MTX slow diffusion. The hydrophobic 
drug in the external layer may partition through the polymer phase 
to the cubic phase. The drug release rate of all the formulation was 
observed varying from 1.55-1.89 %/h showing a greater potential 
for the sustained release pattern of the cubosomes nano-formulation 
whereas gel showed a release of 23 %/h. Cubosomes showed a 
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controlled drug release with t50 approximately 16 h. The cumulative 
release percent almost achieved 100 % after 48 h, showing a 
complete release ability of formulation. Formulations F3 and F4 
showed better release, droplet size and other characteristic 
properties. This pattern of slow release of the drug can be related to 
the slow expulsion due entrapment of the drug [38]. 
 
 




Fig. 5: Drug release kinetics of various models (mean±SD; n=6) 
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Release kinetics  
The acquired in vitro release information was joined into different 
release kinetic models. The Highest estimation of the correlation 
coefficient was watched for the Higuchi matrix model (R2=0.9959) 
and it pursues non-fickian discharge. Higuchi depicts the drug 
release as a diffusion mechanism dependent on the Fick's law, 
contingent upon the square foundation of time. [39] This 
connection can be utilized to portray the drug dissolution from 
different sorts of altered or controlled release pharmaceutical 
dosage forms (fig. 5) [38]. 
Stability studies  
The developed Methotrexate cubosomes were observed for particle 
size distribution, phase separation, Precipitation, % Entrapment 
efficiency and % Drug loading after keeping the product in specified 
conditions (table 3). 
  
Table 3: Stability data (mean±SD; n=6) 
Condition Time Phase separation Precipitate Particle size±SD PDI ±SD % Entrapment % Drug loading 
Initial 0 No No 78.45±0.42 -30.42±0.11 87.28±0.51 14.40±4.21 
25±2 °C/65±5%RH 3M No No 69.32±5.31 -31.26±0.48 85.72±4.36 13.37±3.91 
6M No No 95.18±1.42 -30.77±8.22 83.37±0.42 13.04±6.31 
40±2 °C/75±5%RH;  3M No No 102.48±4.71 -29.46±0.11 80.50±3.17 12.94±4.20 
6M No No 95.18±1.42 -29.42±5.15 76.20±4.19 12.90±3.21 
 
It was found that the formulation remained stable during 6 mo of 
stability studies. According to the results received, the kinetic 
analysis showed that the degradation of Methotrexate was found to 
follow zero-order reaction for the cubosomes formulation F4, based 
on the values of the correlation coefficient (r). 
CONCLUSION 
MTX is the best helpful specialist accessible to treat an assortment of 
malignancies, for example, non-Hodgkin's lymphoma, osteosarcoma, 
choriocarcinoma, lymphocytic leukemia, and head, neck, and bosom 
diseases. Utilized against non-neoplastic conditions, for example, 
serious psoriasis and immune system illnesses, for example, RA. 
Methotrexate cubosomes are additionally a novel medication 
conveyance framework and in this examination, it has been created 
and contemplated. The created conveyance framework is viewed as 
a means of fruitful treatment of rheumatoid as it gives controlled 
conveyance of the medication in human by means of the noninvasive 
skin course with additionally continuing, less successive dosing.  
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